[
  {
    "section": "section:1",
    "title": "A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Nonâ€“Small-Cell Lung Cancer"
  },
  {
    "section": "section:2",
    "title": "MATERIALS AND METHODS"
  },
  {
    "section": "section:3",
    "title": "Eligibility Criteria"
  },
  {
    "section": "section:3",
    "title": "Treatment and Efficacy Assessments"
  },
  {
    "section": "section:3",
    "title": "Safety Assessment"
  },
  {
    "section": "section:3",
    "title": "Biomarker Measurements"
  },
  {
    "section": "section:3",
    "title": "Statistics"
  },
  {
    "section": "section:2",
    "title": "RESULTS"
  },
  {
    "section": "section:3",
    "title": "Patient Characteristics"
  },
  {
    "section": "section:3",
    "title": "Treatment Delivered"
  },
  {
    "section": "section:3",
    "title": "Efficacy Evaluation"
  },
  {
    "section": "section:3",
    "title": "Safety and Tolerability"
  },
  {
    "section": "section:2",
    "title": "DISCUSSION"
  },
  {
    "section": "section:2",
    "title": "REFERENCES"
  }
]